Sign in
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022
Treatment Burden and Vision Analysis of Anti-VEGF Therapies for the Treatment of Neovascular AMD
Rahul Komati, MD
Annual Meeting Talks
2020
Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Carl J Danzig, MD
Category: AMD - Neovascular